ICPT News and Press, Intercept Pharmaceuticals Inc. From 09/21/22

Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million Company well-positioned to drive continued growth in PBC, progress NASH program, expand and advance pipeline MORRISTOWN, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE)...

Intercept Pharmaceuticals ( NASDAQ: ICPT ) Ocaliva (obeticholic acid) demonstrated a transplant-free survival benefit in patients with primary biliary cholangitis based on clinical trial and real-world data compared to those who didn't receive the treatment. Patients on Oc...

Combined clinical trial and real-world data with six years of follow-up provides important evidence of efficacy Analysis compares findings from the Phase 3 POISE trial and open-label extension to natural history data from the Global PBC and UK-PBC patient registries MORRIS...

Summary Despite the recent resurgence, many biotech innovators are still trading at a fraction of their intrinsic value. In studying the biotech landscape, I recently uncovered another promising innovator dubbed Akero Therapeutics. With the recent robust Phase 2b data, Akero i...

MORRISTOWN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President ...

Intercept Pharmaceuticals ( NASDAQ: ICPT ), a biotech focused on liver diseases, announced exchange agreements on Friday to repurchase nearly $44.5M worth of convertible debt for cash and common stock following a similar deleveraging strategy disclosed in August. The priva...

MORRISTOWN, N.J., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating...

Intercept Pharmaceuticals ( NASDAQ: ICPT ) has entered into privately negotiated agreements to repurchase $327.9M of its secured convertible debt using a combination of cash and equity, the biopharmaceutical company announced on Friday . The repurchase is among a series of...

MORRISTOWN, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced to...

MORRISTOWN, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the management team of I...